Direct-to-Employer Drug Purchasing Emerges as Companies Navigate High Prescription Costs

Key Takeaways

• Employers purchase drugs directly from manufacturers.
• Platform initially includes Eli Lilly’s Zepbound KwikPen.
• Aims to cut GLP‑1 and other high drug costs.
• Employers request expansion to top ten brand drugs.
• Could disrupt traditional PBM‑mediated distribution.

Summary

Jay Bregman, CEO of Andel, unveiled a direct‑to‑employer medication platform that lets companies purchase drugs straight from manufacturers, starting with Eli Lilly’s Zepbound KwikPen. The model bypasses PBMs and insurers, aiming to lower out‑of‑pocket costs and curb rising spend on high‑priced drugs such as GLP‑1s. Employers see the approach as a way to avoid restrictive utilization‑management tactics and are asking to expand it to their top ten cost‑driving branded drugs. Bregman predicts the model could reshape pharmaceutical distribution and challenge the PBM‑centric status quo.

Pulse Analysis

The surge in specialty drug prices, highlighted by GLP‑1 agonists that can exceed $1,000 per month, has placed a heavy burden on employer‑sponsored health plans. Traditional pharmacy benefit managers (PBMs) negotiate rebates and impose utilization‑management tools such as prior authorizations and step therapy, but these mechanisms often add administrative friction without delivering proportional cost relief. As a result, benefits committees are increasingly scrutinizing spend and, in some cases, scaling back coverage. This fiscal pressure creates fertile ground for alternative procurement models that promise transparency and direct price negotiation.

Andel’s newly launched direct‑to‑employer platform offers a pragmatic response. By allowing companies to buy medications straight from manufacturers—beginning with Eli Lilly’s Zepbound KwikPen—employers can bypass PBM mark‑ups and negotiate volume‑based discounts while subsidizing employee out‑of‑pocket expenses. Early adopters report streamlined access, reduced administrative overhead, and measurable savings on high‑cost branded therapies. The model also gives employers data visibility into spend patterns, enabling them to target the ten most expensive drugs for similar arrangements, thereby extending the cost‑containment impact beyond GLP‑1s.

Industry analysts view this disintermediation as a potential inflection point for pharmaceutical distribution. If employers scale the approach, PBMs could see a contraction of their traditional revenue streams, prompting a strategic shift toward value‑based services or deeper integration with health plans. Regulatory bodies may also scrutinize the model for compliance with rebate and antitrust rules. Nonetheless, the promise of lower drug prices and improved member experience positions direct‑to‑employer purchasing as a catalyst for broader market re‑segmentation.